Ayelet Shai

ORCID: 0000-0001-9502-8441
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ovarian cancer diagnosis and treatment
  • Cancer, Lipids, and Metabolism
  • Breast Cancer Treatment Studies
  • Genetic factors in colorectal cancer
  • Lipoproteins and Cardiovascular Health
  • Autopsy Techniques and Outcomes
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Cancer Diagnosis and Treatment
  • Cannabis and Cannabinoid Research
  • Traumatic Ocular and Foreign Body Injuries
  • Cancer-related molecular mechanisms research
  • Cancer Immunotherapy and Biomarkers
  • HER2/EGFR in Cancer Research
  • MicroRNA in disease regulation
  • Colorectal Cancer Treatments and Studies
  • Liver Disease Diagnosis and Treatment
  • Cancer survivorship and care
  • Grief, Bereavement, and Mental Health
  • Prostate Cancer Treatment and Research
  • BRCA gene mutations in cancer
  • Medical Imaging Techniques and Applications
  • PARP inhibition in cancer therapy
  • Gut microbiota and health
  • Breast Lesions and Carcinomas
  • Estrogen and related hormone effects

Rambam Health Care Campus
2023-2025

Technion – Israel Institute of Technology
2024-2025

Western Galilee Hospital
2016-2024

University of Haifa
2024

Bar-Ilan University
2016-2022

Ministry of Health of the Russian Federation
2016-2020

Russian Federal Centre of Forensic Science of the Ministry of Justice of the Russian Federation
2017-2018

Russian Children's Clinical Hospital
2016

Carmel Medical Center
2011-2015

Clalit Health Services
2003-2014

Shannon N. Westin Kathleen N. Moore Hye Sook Chon Jung‐Yun Lee Jessica Thomes Pepin and 95 more Michael J. Sundborg Ayelet Shai Joseph de la Garza Shin Nishio Michael A. Gold Ke Wang Kristi McIntyre Todd D. Tillmanns Stephanie V. Blank Jihong Liu Michael McCollum Fernando Contreras Mejía Tadaaki Nishikawa Kathryn P. Pennington Zoltán Novàk Andréia Cristina de Melo Jalid Sehouli Dagmara Klasa-Mazurkiewicz Christos Papadimitriou Marta Gil-Martín Birutė Brasiūnienė Conor Donnelly Paula Michelle del Rosario Xiaochun Liu Els Van Nieuwenhuysen Sophia Frentzas Ganessan Kichendasse Bo Gao Tarek Meniawy Linda Mileshkin Gary Richardson Felicia Roncolato Jean‐François Baurain Maryam Bourhaba Eveline Cuypere Philip R. Debruyne Hannelore Denys Frédéric Forget Brigitte Honhon E. Joosens Els Van Nieuwenhuysen Vanessa da Costa Miranda Andréia Cristina de Melo Joao Daniel Guedes Charles Andreé Joseph de Pádua Nicolas Lazaretti Carolina Martins Vieira André Mattar Daniela Neves Palmeiro Christina Pimentel Oppermann Kussler Pedro Emanuel Rubini Liedke João Soares Nunes Katsuki Arima Tiscoski Allan Covens Lara De Guerké Prafull Ghatage Lucy Gilbert Susie Lau Amit M. Oza Diane Provencher Omar Touhami Congzhu Li Danbo Wang Ge Lou Zhu Genhai Guiling Li Shi Hong Hong Zheng Hongwu Wen Jihong Liu Jing Wang Ke Wang Kui Jiang Li Li Wang Li Min Hao Qi Zhou Gao Qinglei Sihai Liao Songling Zhang Weidong Zhao Xiaohua Wu Wuliang Wang Rutie Yin Ying Cheng Yu Zhang Zhiqing Liang Fernando Contreras Mejía Ángel Luis Martín de Francisco Hernández Carolina Ortiz Lopez Carlos Javier Pacheco Pedro Luis Ramos Guette Jaime Rendon Pereira Julian Rivera Diaz Tomás Sánchez Villegas

Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit mismatch repair (MMR)-deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially pMMR

10.1200/jco.23.02132 article EN cc-by-nc-nd Journal of Clinical Oncology 2023-10-21

The BNT162b2 vaccine was shown to be highly effective in reducing the risk of COVID-19 infection healthy individuals and patients with chronic disease. However, there are little data regarding its efficacy treated for cancer. We analyzed humoral response following vaccination second dose 140 solid malignancies who were receiving anti-cancer therapy at time 215 participants had not been diagnosed Multivariate analysis performed, followed by matching two groups age, gender days from...

10.3390/cancers13164191 article EN Cancers 2021-08-20

In the last decade use of medical cannabis (MC) for palliative cancer treatment has risen. However, choice between products is arbitrary and most patients are using Tetrahydrocannabinol (THC)-dominant products. this study, we aimed to assess short-term outcomes MC prescribed by oncologists in relation type they receive. A comparative analysis was used differences effectiveness safety THC-dominant (n = 56, 52%), cannabidiol (CBD)-dominant 19, 18%), mixed 33, 30%) treatments. Oncology 108)...

10.3390/ph13120435 article EN cc-by Pharmaceuticals 2020-11-30

// Avital Gilam 1,* , Ayelet Shai 2,3,* Itamar Ashkenazi 4 Liat Appel Sarid 2,3 Assi Drobot 2 Amitai Bickel and Noam Shomron 1 Sackler Faculty of Medicine, Tel Aviv University, Aviv, Israel Oncology Department, Galilee Medical Center, Nahariya, 3 Bar Illan Zefad, Hillel Yaffe Hedera, * These authors have contributed equally to this work Correspondence to: Shomron, email: Keywords : breast cancer, progesterone receptor, microRNA, miR-181a, miR-23a Received January 17, 2017 Accepted 25,...

10.18632/oncotarget.15657 article EN Oncotarget 2017-02-23

The use of medical cannabis (MC) to treat cancer-related symptoms is rising. However, there a lack long-term trials assess the benefits and safety MC treatment in this population. In work, we followed up prospectively longitudinally on effectiveness treatment. Oncology patients reported multiple before after initiation at one-, three-, 6-month follow-ups. Oncologists patients' disease characteristics. Intention-to-treat models were used changes outcomes from baseline. was initiated by 324...

10.3389/fpain.2022.861037 article EN cc-by Frontiers in Pain Research 2022-05-20

Abstract Background Adjuvant chemotherapy induces weight gain, glucose intolerance, and hypertension in about a third of women. The mechanisms underlying these events have not been defined. This study assessed the association between microbiome gain patients treated with adjuvant for breast gynecological cancers. Methods Patients were recruited before starting therapy. Weight height measured treatment 4–6 weeks after completion. was defined as an increase 3% or more body weight. A stool...

10.1186/s12916-020-01751-2 article EN cc-by BMC Medicine 2020-10-21

Pain and subjective cognitive decline (SCD) are common sequala of breast cancer (BC) treatment. Adverse childhood experiences (ACEs) associated with pain adverse health outcomes in noncancer population. Sense coherence (SOC) reflects the disposition that life is manageable predictable. danger (SOD) extent perceived to oneself family from a specific stressor. We aimed assess if ACEs SCD patients treated for localized BC, whether decreased SOC, increased SOD psychological distress mediate...

10.1016/j.breast.2025.103884 article EN The Breast 2025-01-18

Abstract The presence of bacteria in solid human tumors has been documented for over 100 years. Still, it only recent years that a more thorough characterization this low biomass microbiome and its effects pursued. We have studied tumor biopsies were taken before the initiation treatment with checkpoint inhibitors (CPIs) compared within these samples immune landscape response to therapy. found few bacterial taxa functions highly correlated CPIs. In my talk, I will present our main findings...

10.1158/1538-7445.am2025-sy45-01 article EN Cancer Research 2025-04-25

Introduction As many as 90% of BC survivors suffer from long term sequelae, and use or used cannabis during after treatment to alleviate symptoms. Little is known about the effects chronic in this population. We aimed study patterns survivors. Materials methods a single center cohort study. Participants were patients aged 30–75, diagnosed with stage 1–3 prescribed medical cannabis. Patients included if they completed chemotherapy at least 6 months before entry did not experience disease...

10.1177/10781552251340329 article EN Journal of Oncology Pharmacy Practice 2025-05-05

Introduction IORT is becoming an accepted radiotherapy technique for treatment of early breast cancer. Data regarding the complications are lacking. Objectives Assess nature and risk factors conserving surgery (BCS) intraoperative (IORT) with INTRABEAM®. Methods INTRABEAM® was administered to cancer patients in Carmel Medical Center as part institutional clinical registry project. Three hundred ninety five treated during 2006–2013 were included. Clinical data documented within 1 year...

10.1002/jso.24157 article EN Journal of Surgical Oncology 2016-01-11

KRAS mutations, which are the main cause of pathogenesis lethal pancreatic adenocarcinomas, impair functioning GTPase subunit, thus rendering it constitutively active and signaling intracellular pathways that end with cell transformation. In present study, AsPC-1 line, has a G12D-mutated gene sequence, was utilized as cellular model to test peptide nucleic acid-based antisense technology. The use acids (PNAs) built exhibit improved hybridization specificity have an affinity for complementary...

10.3892/ol.2022.13250 article EN Oncology Letters 2022-02-21

10.1080/15265161.2024.2308139 article EN cc-by-nc-nd The American Journal of Bioethics 2024-03-26

BACKGROUND: Previously, sponsored publications have shown that either terbinafine or itraconazole (pulse regimen) are effective for patients with toenail onychomycosis. However, independent comparative studies lacking.OBJECTIVES: To objectively compare treatment and in onychomycosis.METHODS: The effectiveness of (250 mg/day 3 months) versus pulse regimen (400 the first week each month, three cycles) was retrospectively evaluated onychomycosis using mycological tests subjective outcome...

10.1080/09546630310017834 article EN Journal of Dermatological Treatment 2003-12-01

•We report a case of malignant cardiac tamponade secondary to ovarian carcinoma•We emphasize the quick and fatal outcome such complication•It seems that aggressive treatment offers longest overall survival.

10.1016/j.gynor.2014.06.001 article EN cc-by-nc-sa Gynecologic Oncology Reports 2014-06-18

Gastrointestinal fistulae can occur in ovarian cancer patients, usually the setting of advanced relapsed disease. Treatment typically involves immediate surgery. Here, we describe a case an abscess resulting from intestinal fistula as first manifestation epithelial cancer, and review current literature on this subject. The patient was successfully treated with combination chemotherapy, antibiotics, delayed Optimal debulking achieved without need for bowel resection. This report is...

10.3747/co.20.1196 article EN cc-by Current Oncology 2013-02-01
Coming Soon ...